152 related articles for article (PubMed ID: 38297352)
1. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Lynce F; Stevens LE; Li Z; Brock JE; Gulvady A; Huang Y; Nakhlis F; Patel A; Force JM; Haddad TC; Ueno N; Stearns V; Wolff AC; Clark AS; Bellon JR; Richardson ET; Balko JM; Krop IE; Winer EP; Lange P; Hwang ES; King TA; Tolaney SM; Thompson A; Gupta GP; Mittendorf EA; Regan MM; Overmoyer B; Polyak K
Breast Cancer Res; 2024 Jan; 26(1):20. PubMed ID: 38297352
[TBL] [Abstract][Full Text] [Related]
2. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.
Symonds L; Jenkins I; Linden HM; Kurland B; Gralow JR; Gadi VVK; Ellis GK; Wu Q; Rodler E; Chalasani P; Chai X; Riedel J; Scca Network Investigators ; Stopeck A; Brown-Glaberman U; Specht JM
Clin Breast Cancer; 2022 Jan; 22(1):32-42. PubMed ID: 34158245
[TBL] [Abstract][Full Text] [Related]
4. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
5. JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.
Stevens LE; Peluffo G; Qiu X; Temko D; Fassl A; Li Z; Trinh A; Seehawer M; Jovanović B; Alečković M; Wilde CM; Geck RC; Shu S; Kingston NL; Harper NW; Almendro V; Pyke AL; Egri SB; Papanastasiou M; Clement K; Zhou N; Walker S; Salas J; Park SY; Frank DA; Meissner A; Jaffe JD; Sicinski P; Toker A; Michor F; Long HW; Overmoyer BA; Polyak K
Cancer Res; 2023 Jan; 83(2):264-284. PubMed ID: 36409824
[TBL] [Abstract][Full Text] [Related]
6. Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.
Palazzo A; Dellapasqua S; Munzone E; Bagnardi V; Mazza M; Cancello G; Ghisini R; Iorfida M; Montagna E; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2018 Aug; 18(4):328-335. PubMed ID: 29486983
[TBL] [Abstract][Full Text] [Related]
7. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
Lynce F; Williams JT; Regan MM; Bunnell CA; Freedman RA; Tolaney SM; Chen WY; Mayer EL; Partridge AH; Winer EP; Overmoyer B
Cancer Chemother Pharmacol; 2021 May; 87(5):673-679. PubMed ID: 33585999
[TBL] [Abstract][Full Text] [Related]
9. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.
Matsuda N; Wang X; Lim B; Krishnamurthy S; Alvarez RH; Willey JS; Parker CA; Song J; Shen Y; Hu J; Wu W; Li N; Babiera GV; Murray JL; Arun BK; Brewster AM; Reuben JM; Stauder MC; Barnett CM; Woodward WA; Le-Petross HTC; Lucci A; DeSnyder SM; Tripathy D; Valero V; Ueno NT
JAMA Oncol; 2018 Sep; 4(9):1207-1213. PubMed ID: 29879283
[TBL] [Abstract][Full Text] [Related]
11. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
Forero-Torres A; Varley KE; Abramson VG; Li Y; Vaklavas C; Lin NU; Liu MC; Rugo HS; Nanda R; Storniolo AM; Traina TA; Patil S; Van Poznak CH; Nangia JR; Irvin WJ; Krontiras H; De Los Santos JF; Haluska P; Grizzle W; Myers RM; Wolff AC;
Clin Cancer Res; 2015 Jun; 21(12):2722-9. PubMed ID: 25779953
[TBL] [Abstract][Full Text] [Related]
12. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
13. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Vergis N; Phillips R; Cornelius V; Katsarou A; Youngstein T; Cook L; Willicombe M; Pilay C; Shturova T; Almonte M; Charania A; Turner R; Kon OM; Cooke G; Thursz M; Cherlin S; Wason J; Milojkovic D; Innes AJ; Cooper N
Trials; 2021 Apr; 22(1):270. PubMed ID: 33845867
[TBL] [Abstract][Full Text] [Related]
14. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
16. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J
Breast Cancer Res Treat; 2015 Nov; 154(2):351-7. PubMed ID: 26536871
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
19. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
20. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
